Curium has received marketing authorization in Switzerland for its product PYLCLARI® (Piflufolastat (18F)), which is indicated for detecting prostate-specific membrane antigen (PSMA) positive lesions in prostate cancer patients using positron emission tomography (PET). This follows prior approval from the European Commission in July 2023, and PYLCLARI® is now available in 12 European countries. The distribution in Switzerland will be managed by b.e. Imaging, which will expand its partnership with Curium. The news highlights an important development in the availability of diagnostic radiopharmaceuticals for prostate cancer in Switzerland, where prostate cancer is the most common cancer among men.
Mon, 12 May 2025 11:07:18 GMT | GlobeNewswire